BioSpace News Archive

According to the latest research report by Transparency Market Research, the global dental consumables market is projected to witness an intense competition in its vendor landscape.

Transparency Market Research has published a new report titled, ‘Compression Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its poster abstract for the American Thoracic Society (ATS) 2020 International Conference was published in today’s edition of the American Journal of Respiratory and Critical Care Medicine

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s potential across treatment settings and formulations LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that six abstracts presenting clinically relevant findi

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab

Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that due to the emerging health impact of the coronavirus pandemic, the Company has changed the location of its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) to its corporate headquarters at 490 Lapp Road, Malvern, Pennsylvania 19355.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the market closes on Wednesday, May 6, 2020.

Omnicell, Inc. (NASDAQ: OMCL), today announced that due to the public health impact of the novel coronavirus (COVID-19) pandemic and to protect the health and wellbeing of its employees, stockholders and the broader community, the Company will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format only, via live audio webcast.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19